Bedrijfsoverzicht
ImmunityBio, Inc. is a biotechnology enterprise dedicated to innovating, developing, and commercializing next-generation immunotherapies aimed at activating the patient's immune system to provide durable protection against cancer and infectious diseases. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, where the primary focus is on advancing scientific discoveries into clinical applications and therapeutic products. ImmunityBio operates at a significant scale with a market capitalization of $7.52B, an annual revenue of $113.29M, and an employee base of 684 individuals. The combination of a $7.52B market cap and $113.29M in revenue indicates that the market values the company's intellectual property and pipeline assets at a premium, despite the fact that the company currently reports a net loss, which is typical for firms in the early stages of commercializing complex biologic products.
Financiële gezondheid
The company reported revenue of $113.29M for the trailing twelve months, while the net income stood at $-351,398,016, revealing a substantial gap between top-line sales and bottom-line profitability that highlights a cost structure dominated by high research and development expenditures. EBITDA for the period was recorded at $-240,602,000, further illustrating the capital-intensive nature of the business model where operational cash burn outpaces operating earnings. Free cash flow was determined to be $-213,356,992, which signifies that the company is currently consuming cash reserves to fund its operations and pipeline development rather than generating surplus cash for distribution or debt repayment. The gross margin stands at 99.3%, indicating highly efficient production costs relative to revenue, whereas the operating margin is -169.0% and the profit margin is 0.0%, reflecting the heavy overhead and loss-making status typical of biotech firms in the pre-revenue or low-revenue commercialization phases. On the balance sheet, total cash holdings amount to $242.82M, which is insufficient to cover total debt of $844.72M, suggesting a leveraged position where liabilities significantly exceed liquid assets. The current ratio is 5.10, indicating that the company holds ample short-term assets relative to its short-term obligations, providing a buffer against immediate liquidity pressures despite the net debt position. Return on Equity is listed as N/A due to the lack of positive equity returns, while Return on Assets is -36.2%, which reveals that the company is currently generating negative returns on its total asset base as it invests heavily in future growth potential.
Waarderingsbeoordeling
The trailing P/E ratio is N/A because the company is unprofitable, while the forward P/E is -364.00, implying that analysts are pricing in significant future earnings growth that is required to justify the current stock price. The price-to-book ratio is -14.71, indicating that the market is valuing the company at a negative multiple of its book value, which often occurs when a firm's liabilities exceed its tangible assets on a pro-forma basis. The price-to-sales ratio is 66.36, suggesting that the market places a very high valuation on every dollar of revenue generated, a metric often used to value growth companies that lack earnings. Additionally, the EV/EBITDA stands at -33.61, which further underscores the speculative nature of the valuation given the negative earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $12.43 and a 52-week low of $1.83, meaning the current price sits somewhere within this wide range, reflecting high volatility and uncertainty surrounding the company's commercialization milestones. The beta value is 0.06, indicating that the stock's price volatility is extremely low relative to the broader market, which is an unusual characteristic for a biotechnology stock and suggests the price may be heavily influenced by binary event risk rather than continuous trading volume dynamics.
Growth & Income
Revenue growth year-over-year is reported at 407.0%, demonstrating an aggressive expansion in top-line sales, whereas earnings growth is N/A due to the company's consistent losses, implying that revenue expansion is not yet translating into profitability at the current scale. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available cash flow is reinvested back into the business to fund research, development, and clinical trials rather than being distributed to shareholders. This reinvestment strategy is standard for biotechnology companies that prioritize pipeline advancement over income generation for investors. Overall, the growth and income profile is characterized by explosive revenue expansion coupled with a total absence of dividend income, positioning the investment entirely on the potential for future equity appreciation upon successful product commercialization and profit generation.